ResMed Inc. (ASX: $RMD) Q4 FY24 results overview

ResMed Inc. (ASX: $RMD) has reported its financial results for the fourth quarter of fiscal year 2024, ending June 30, 2024. The company achieved a 9% year-over-year revenue growth, with operating profit up by 38%. The operating cash flow stood at $440 million, and the quarterly dividend has been increased by 10% to $0.53 per share. ResMed Inc. also announced its plans to host an Investor Day on September 30, 2024. The company's webcast of the conference call will be available at http://investor.resmed.com at 4:30 p.m. ET today.

Executive commentary on Q4 FY24 performance

Mick Farrell, Chairman & CEO of ResMed, expressed satisfaction with the company's performance, stating, 'Our fourth quarter and full-year fiscal year 2024 results demonstrate strong performance across all sectors of our business. Ongoing patient and customer demand for our best-in-class products and software solutions is incredibly strong, driving solid growth across our devices, masks, and software businesses.' Farrell also highlighted the company's focus on increasing market penetration and accelerating growth, emphasizing their position as the market leader in underpenetrated markets.

Summary of Q4 FY24 results and outlook

ResMed Inc. has reported strong financial results for the fourth quarter of fiscal year 2024, with significant revenue growth and improved operating profit. The company's focus on operating excellence, cost discipline, and profitable growth acceleration has resulted in gross margin expansion, strong operating leverage, and double-digit growth in bottom-line profitability. With ongoing patient and customer demand for their products and software solutions, ResMed Inc. aims to drive increased market penetration and accelerate growth. The company's plans to host an Investor Day on September 30, 2024, indicate a proactive approach to engaging with stakeholders and showcasing their future strategies and initiatives.